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Abstract
Background: Cytokines, chemokines, adipocytokines, soluble cell receptors, and immune activation markers play an
important role in immune responsiveness and can provide prognostic value since they reflect underlying conditions
and disease states. This study was undertaken to investigate the components of biological variation for various laboratory
tests of blood immunological biomarkers.
Results: Estimates of intra-individual coefficient of variation (CVI) and inter-individual coefficient of variation (CVG)
were examined for blood immunological biomarkers. Biomarkers with CVI < 10% for both genders were CD3, CD4,
and CD8 T-cells, serum levels of soluble cluster of differentiation 14 (sCD14), sCD163, and soluble glycoprotein 130 (sgp130).
The CVI for serum levels of adiponectin, interleukin-1 receptor antagonist (IL-1Ra), macrophage inflammatory protein 1 beta
(MIP-1β), soluble CD40 Ligand (sCD40L), soluble interleukin-2 receptor alpha (sIL-2Rα), soluble interleukin-6 receptor (sIL-6R),
soluble tumor necrosis factor receptor II (sTNF-RII), and tumor necrosis factor alpha (TNF-α) were between 11
and 20%. Biomarkers with CVG < 20% were CD3 T-cell, and serum concentrations of sCD14, sCD40L, and sgp130. The
biomarkers with CVG > 40% were adiponectin, IL-1ra, leptin, MIP-1β, sCD163, and sIL-2Rα.
Conclusion: The biological variations of biomarkers have important monitoring value for longitudinal investigation and
are essential for quality specification of tests that are performed in the laboratory. The CVI was relatively small while CVG
was comparatively large and mean values of each biomarker vary between subjects. The individuality of biomarkers
significantly influences reference interval values. A majority of the biomarkers in this study had strong individuality and
the result of each biomarker should be cautiously interpreted if using established reference interval values. Comparison
of a patient’s test result with previous ones may be more useful than the usage of conventional reference values.
Keywords: Chemokine, Cytokines, Immune activation, Interleukin, Soluble markers
Background
Immunological biomarkers such as serum cytokines,
chemokines, adipocytokines, soluble forms of cell recep-
tors, and immune activation markers can serve as
surrogate markers for cellular activation and play an
important role in the function of the immune system.
Complex interactions between immune cells of the
innate and adaptive immune systems are modified by
the release of a variety of cell mediators that trigger
inflammatory responses which help to eliminate and
destroy foreign antigens. They serve numerous functions
within our immune system and interact with specific cell
types that correspond with different stages of disease.
Changes in the levels of these biomarkers along with
changes in lymphocyte subset activity can provide im-
portant prognostic value by reflecting underlying disease
conditions [1–7]. Thus, it is essential to be able to detect
laboratory and clinically relevant changes by accurately
measuring those blood biomarkers, making them poten-
tially beneficial for the monitoring, diagnosis, and follow
up of various diseases.
Clinical usefulness of these biomarkers depends upon:
1) their ability to account for a significant portion of the
disease being evaluated; 2) the ability to be accurately, re-
producibly, and reliably measured; and 3) the availability
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of the assay for widespread application [8]. Since blood
levels of immunological biomarkers differ widely between
individuals based on their gender, age, and other factors,
baseline concentrations of biomarkers should be estab-
lished for healthy individuals. In addition, the suitable
biomarkers should have a low temporal intra-individual
variability in healthy subjects otherwise any significant
changes might not necessarily reflect disease processes.
Biological variation (BV) is often the most important
source of variation over time for certain biomarkers and
marked changes can occur during the neonatal, childhood,
puberty, menopause, and aging process. In addition,
certain biomarkers have biological rhythms that can vary
diurnally, monthly, or seasonally [9].
There are a limited numbers of studies that have exam-
ined the BV of immunological biomarkers and lymphocyte
phenotype and a majority of published studies have only
investigated the BV associated with clinical chemistry and
hematological biomarkers [10].
In this study we evaluated the short term (six weeks)
temporal intra-individual variation (CVI) and inter-indi-
vidual variation (CVG) of commonly requested laboratory
tests for immunological biomarkers of serum/plasma
cytokines such as interleukin-1 beta (IL-1β), interleukin-6
(IL-6), interleukin-12p70 (IL-12p70), interleukin-1 recep-
tor antagonist (IL-1Ra), interferon gamma (IFN-γ), and
tumor necrosis alpha (TNF-α); chemokines such as inter-
leukin-8 (IL-8), macrophage inflammatory protein 1 alpha
(MIP-1α) or CCL3, macrophage inflammatory protein 1
beta (MIP-1β) or CCL4, and regulated upon activation
normal T cell expressed and secreted (RANTES) or CCL5;
adipocytokines such as adiponectin and leptin; blood
soluble forms of cell surface receptors such as soluble
cluster of differentiation (CD)14 (sCD14), soluble CD25
(sCD25) or IL-2Rα, soluble CD40 Ligand (sCD40L),
soluble CD120b (sCD120b) or sTNF-RII, soluble CD126
(sCD126) or sIL-6R, soluble CD130 (sCD130) or sgp130,
and soluble CD163 (sCD163); immune activation markers
such as neopterin and T and B lymphocyte phenotype. The
clinical and research significance for each biomarker is out-
lined in the Additional file 4.
The aim of our study was to gather more information
about the CVI and CVG of the biomarkers in healthy
individuals and influences of CVI and CVG on the popu-
lation based reference values as well as setting quality
specification goals for precision, bias, and total error
allowable of laboratory tests for those markers.
Results
The mean serum concentration of five groups (cyto-
kines, chemokines, adipocytokines, soluble cell receptors,
and immune activation markers) of biomarkers and the
mean percentage of each lymphocyte subset for twelve
normal participants, along with coefficients of variation
for analytical (CVA), intra-individual (CVI), and inter-in-
dividual (CVG) for six women, six men, and both
genders are shown in Tables 1 and 2. Measured serum
levels of IL-12p70 and MIP-1α for all twelve participants
were lower than the minimum detectable dose.
Biological variation (BV) is expressed as a percentage
and intra-individual variation was relatively small while in-
ter-individual was relatively large. Biomarkers with a CVI <
10% for both genders were the percentage of CD3+,
CD4+, and CD8+ T-cells; and serum concentrations of
sCD14, sgp130, and sCD163. The CVI for IL-1Ra, TNF-α,
MIP-1β, adiponectin, sIL2Rα, sCD40L, sTNF-RII, and
sIL6R ranged from 11 to 20%.
Biomarkers with a CVG < 20% were the percentage of
CD3+ T-cells and serum concentrations of sCD14,
sCD40L, and sgp130. Biomarkers with the most inter-in-
dividual variability (CVG > 40%) were serum concentra-
tions of IL-1Ra, MIP-1β, adiponectin, leptin, sIL2Rα, and
sCD163.
Women had higher CVI for 10 out of 18 serum bio-
markers compared to men, while men had a higher CVG
for 13 of 18 serum biomarkers. CVG was not calculable
in men for IL-1β, because the mean square of inter-indi-
vidual was smaller than inter-individual (Table 1). The
influence of biomarker individuality on conventional
population reference values and interpretation of labora-
tory test results visualized by the mean and absolute
range of each biomarker for the twelve healthy subjects
is presented in Fig. 1 for IL-1β (A), IL-6 (B), IFN-γ (C),
IL-1Ra (D), TNF-α (E), IL-8 (F), MIP-1β (G), RANTES
(H), and sCD14 (I); in Fig. 2 for sCD40L (A), sCD163
(B), sIL-6R (C), sIL-2Rα (D), sTNF-RII (E), sgp130 (F),
Adiponectin (G), Leptin (H), and neopterin (I); and in
Fig. 3 for CD4 (A), CD8 (B), CD19 (C), and CD56/16
(D).
The desirable quality specifications for imprecision
and bias (%), total error allowable at 95 and 99%, and
the indices of individuality and heterogeneity for each of
the biomarkers based on biological variation are calcu-
lated and summarized in Tables 3 and 4.
In addition, the mean, median, and inter–quartile
range (IQR) of the biomarkers were calculated for six
male, six female, and both genders, and presented in
Additional file 1: Table S1a and Table S1b.
The Spearman’s correlation was assessed to determine
the relationship among the 18 serum biomarkers and 5
lymphocyte phenotypes of 12 subjects with six visits (total
of 71 observations for each marker). There were both
positive and negative statistically significant (p < 0.05) cor-
relation coefficients (R) among the markers, ranging from
very weak to strong as shown in Additional file 2: Table
S2. The markers with strong positive rho (r = 0.65, p =
0.0001) were serum levels of TNF-α and IL-1ra and
markers with strong negative rho (r = − 0.65, p = 0.0001)
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were serum levels of serum sIL-6R and CD4+ cells. The
markers with weak positive rho (r = 0.24, p = 0.043) were
serum levels of sCD14 and MIP-1β and the markers with
weak negative rho (r = − 0.24, p = 0.047) were serum levels
of sCD14 and sIL-2R. The correlation for eight markers
(rho and p values), from strong correlation to no corre-
lation, were depicted in Additional file 3: Figure S1 and
Figure S2.
Discussion
Obtaining a reliable test result requires that all sources
of variation should be minimized and components of
biological variation (CVI and CVG) properly evaluated
and managed during the entire process that leads to the
final laboratory test report [11].
One of the eventual goals in the study of these bio-
markers is to identify those with small biological variation,
making them more appropriate for clinical use. It is not
surprising that in healthy individuals, biomarker concen-
trations measured every six months for a period of five
years are likely to display greater biological variation than
biomarkers measured at a fixed time of the day for a
period of 2 to 3months [12].
The study was done based on the framework of the
published study of Ford et al. [13]. Our study has some
limitations due to the samples size of twelve participants
and short period of follow up of six weeks which were
Table 1 Mean value of biomarkers, analytical (CVA), intra-individual (CVI), and inter-individual (CVG) components of variation for
eighteen serum biomarkers
Weighted CVI (%) CVG(%)
Biomarker (unit) Mean CVA (%) Male Female Both Male Female Both
Group I IL-1β (pg/mL) 0.157 4.0a 38.0 22.0 30.9 NCb 42.0 27.0
IL-6 (pg/mL) 0.961 6.4 23.0 20.0 21.5 33.0 19.0 26.4
IL-1Ra (pg/mL) 419.0 6.0 15.0 17.3 17.0 42.0 37.7 43.0
IFN-γ (U/L) 278 13.5 29.0 34.0 31.0 10.8 33.0 22.0
TNF-α (pg/ml) 12.63 8.2 7.9 14.2 12.7 24.3 31.7 27.2
Group II IL-8 (pg/mL) 12.16 3.5a 24.0 61.6 51.4 32.0 28.0 30.2
MIP-1β (pg/mL) 101.0 4.5 18.0 22.0 20.0 22.0 82.0 57.0
RANTES (ng/mL)) 32.71 3.2 27.0 23.0 24.0 51.0 30.0 39.0
Group III Adiponectin (μg/mL) 6.29 3.7 12.0 17.0 15.9 49.0 42.0 48.1
Leptin (ng/mL) 7.66 7.1 18.0 31.0 31.0 66.0 50.0 68.0
Group IV sCD14 (ng/mL) 1435.0 2.8 8.8 7.6 8.0 16.0 6.1 11.4
sCD40L (ng/mL) 6.02 3.0 14.5 12.7 13.2 18.4 12.8 14.6
sCD163 (ng/mL) 543.0 9.5 6.8 6.5 9.0 64.9 50.2 53.8
sgp130 (ng/mL) 281.0 4.8 4.4 7.5 7.0 12.5 10.4 15.0
sIL-2Rα (pg/mL) 796.0 3.6 9.0 19.0 15.1 34.0 49.0 41.7
sIL-6R (ng/mL) 31.77 3.0a 18.2 12.9 16.3 18.5 18.9 20.3
sTNF-RII (ng/mL) 2.17 10.1 17.6 15.8 17.4 36.0 25.9 28.9
Group V Neopterin (nmol/L) 5.20 6.4 14.5 64.0 35.0 69.4 14.0 37.0
a: CVA calculated from 5 duplicated and two level assay control samples,
b: not calculable (NC)
Table 2 Mean value lymphocyte phenotype, analytical (CVA), intra-individual (CVI), and inter-individual (CVG) components of
variation for five lymphocyte phenotypes
Biomarker Weighted Mean (%) CVA (%) Intra-subject variation
CVI (%)
Inter-subject variation CVG (%)
Phenotype Male Female Both Male Female Both
CD3 (T cells) 73 1.0 3.0 4.1 3.6 8.3 13.6 10.8
CD4 46 3.2 6.8 5.6 6.1 10.5 20.9 20.7
CD8 25 2.4 6.9 5.7 6.7 20.3 43.6 35.5
CD19 (B cells) 12 4.1 22.0 12.6 17.4 27.4 37.0 31.9
CD56/16 (NK cells) 13 5.8 21.4 24.9 23.0 23.4 50.9 37.1
CVA is analytical variation (mean CV of daily QC run for 20 days) expressed as a %CV
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due to practical reasons of financial constraints and
keeping all the participants throughout the entire study.
There is little data available regarding biological vari-
ability for many of the immunological biomarkers (7 out
of 23) examined in this study. Our BV data will provide
valuable information for improving the measurement
and interpretation of blood biomarker levels examined
in our study including setting quality specifications, dis-
tinguishing normal levels from those of a diseased state,
assessing the usefulness of population-based reference
values, selecting the best sample to collect, choosing the
best test, validating a new testing procedure, and imple-
menting an internal quality control procedure.
Biological variation
Available published data for CVI and CVG of immuno-
logical biomarkers are presented in Table 5 for compari-
son purposes [14–17]. Our intra- and inter-individual
variation of adiponectin and IL-1β were nearly identical
with published data, however there are differences in the
intra- and inter-individual variation for other biomarkers
compared to ours. Estimates of CVI and CVG should be
comparable across all the studies but these differences
may be due to the gender ratio, sample size, number of
visits, as well as duration of each study.
Women had higher CVI for 10 out of 18 serum bio-
markers compared to men and this could be due to
menstrual cycle hormones induced changes. A weakness
of the study is that we overlooked the possible influence
of menstrual cycle phases’ and this information was not
collected from the female participants. There was no sig-
nificant difference of CVI for blood level of IL-6 reported
during menstrual cycle [18] and marked fluctuations of
blood levels of TNF-a reported in women [19]. In
addition no significant changes reported in lymphocytes
subsets over the course of a menstrual cycle [20].
Bear in mind that some of the analytes, notably IFN-γ
and IL-1β, are conducted near the minimum detectable
dose (MDD) of the assay and several healthy control and
HIV-positive subjects of our previously study had plasma
levels of markers below MDD. Thus, the low plasma
levels of biomarkers may contribute to high CV [21].
Fig. 1 Mean (filled circle) and absolute range (error bar) for each subject (n=12) over six weeks, for serum level of IL-1β (a), IL-6 (b), IFN-γ (c), IL-
1Ra (d), TNF-α (e), IL-8 (f), MIP-1β (g), RANTES (h), and sCD14 (i)
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Setting analytical goals based on biological variation
The desirable analytical imprecision goal for monitoring
purposes has to be maintained at CVA < 0.50 CVI in
order for the amount of variability that is added to true
test results to be less than 12% (11.8% calculated). Confi-
dence in the precision of an assay allows us to run fewer
internal quality control samples for the biomarker.
The analytical goal of imprecision of biomarkers based
on BV are presented in Tables 3 and 4 and by compar-
ing those data with the CVA obtained (Tables 1 and 2)
for the biomarkers, we can conclude that, with exception
of TNF-α, sCD163, sgp130, sTNF-RII, and CD4+ T-cell,
all other markers met the desirable analytical precision.
CD4+ T-cell, macrophage, and dendritic cells are vulner-
able to human immunodeficiency virus type 1 (HIV-1)
infection because of their CD4 receptor that the HIV-1
virus uses to infect those cells. The production of infec-
tious virion from provirus requires activation of infected
CD4+ T-cell and the CD4+ T-cell count along with HIV
viral load is an important monitoring laboratory tool for
follow up of HIV-1 infected patients receiving treatment.
HIV-1 replicates especially in activated CD4+ T cell.
However, at any given time, most of the CD4+ T cells in
the HIV-1 infected individual are in resting status and
not fully permissible for viral replication. In addition
HIV-1 infected individuals receiving highly active anti-
retroviral therapy (HAART) showing suppression of
viremia and activation of CD4+ T cells [22]. CD40L that
expressed predominantly on activated CD4+ T-cells and
play multiple role in HIV-1 infection [23]. The blood
levels CD4+ T-cells and soluble CD40L (sCD40L) could
be variable during stages of CD4+ T-cell activation by
HIV-1 or other infection, but have not seen variability in
our normal study population.
The numerical goal for desirable bias is also calculated
for each of the markers (Tables 3 and 4) and should be
less than one quarter of the group biological variation. In
a practical sense, the goal for desirable bias is achievable,
but it will be problematic when using many different
methods for the same assay. These biological variation
data of immunological laboratory tests may solve many
analytical problems for the assay. In addition, this would
Fig. 2 Mean (fialled circle) and absolute range (error bar) for each subject (n=12) over six weeks, for serum level of sCD40L (a), sCD163 (b), sIL-6R
(c), sIL-2Rα (d), sTNF-RII (e), sgp130 (f), Adiponectin (g), Leptin (h), and Neopterin (i)
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provide objective analytical goals for manufacturers of
instruments and assay kits [24].
Reference change values
For a disparity in serial test results to be significant, the
difference in numerical results must be greater than the
combined variation in the two serial results and this is
referred to as the reference change value (RCV) [9].
Little intra-individual biological variation for blood im-
munological biomarkers has been published and labora-
tories need to determine their own biological variation for
intra-individual in order to calculate the RCV. The 95%
probability (p < 0.05) for immunological biomarkers RCV
is presented in Tables 3 and 4 and any differences between
two successive quantity results exceeding the RCV for that
biomarker should be further investigated [25].
Utility of reference values
It has well known that CVI is relatively small and mean
value of each individual differ from each other and CVG
relatively large and also our study illustrated the same
pattern for the markers (Figs. 1, 2 and 3). The effect of
index of individuality(I.I) of biomarkers on reference
values were known and when I. I is less than 0.6, con-
ventional population based reference values are limited
in detection of unusual results in contrast when I. I is
more than 1.4 [26]. The I. I with exception of IFN-γ (II =
1.52) and IL-8 (II = 1.70) for all other biomarkers in our
study were at or below 1.14.
All biomarkers in our study had an index of heterogen-
eity (IH) of less than 1.58 which is an indication of the
homogeneity of the collected specimen for within-subject
biological variation. This value determines whether results
obtained from a few subjects can be extrapolated to
almost all subjects [24, 27].
Choosing the best test
Knowledge of the biological variation of biomarkers can
help us to select the most appropriate test for tracking
of disease progression or investigational purposes. In
some cases, there may be multiple tests to accomplish
the same goal, but one may be superior to the others
and BV data can help choose which test to use. For
example, serum sCD14, sCD163, and neopterin tests can
all be used for the evaluation of macrophage activation
and while none of these three tests have diagnostic
value, they are useful for monitoring and follow up
purposes. Soluble CD14 has a RCV of 23, less than both
sCD163 and neopterin, making sCD14 a better monitor-
ing test compared to the other two. However, when
considering the ideal test to perform, one must also keep
in mind that various stimulants may work on the target
cells through different pathways and therefore each
Fig. 3 Mean (filled circle) and percentage range (error bar) for each subject (n=12) over six weeks, for helper T-cell (a), Cytotoxic T-cell (b), B-cell
(c), and NK cell (d)
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biomarker may provide different information about the
disease progression.
Conclusion
The biological variation data generated by our study of
23 biomarkers is the first published data for 16 of the 23
biomarkers and will be valuable for clinical and labora-
tory use, particularly for setting quality specification
goals for immunological biomarker testing purposes.
The usefulness of BV data for healthy subjects is well
documented for having utility in laboratory medicine.
Using serial samples to detect deviations in a patient that
differ from those observed in healthy subjects can be a
sign of analytic error or real biologic changes. These
signals can then be looked into to avoid compromising
patient care, or to further investigate the cause of the
change [26]. Despite having a limited number of subjects
in our study, we found intra-subject variation to be rela-
tively small and inter-subject variation to be relatively
large for the majority of biomarkers that were analyzed.
In our study, most biomarkers had strong individuality,
meaning that the result of a biomarker should be
Table 4 Analytical goals for imprecision, bias, total error allowable (TEa) for p < 0.01 and p < 0.05, reference change value (RCV),
Reliability coefficient (R), index of individuality (II), and index of heterogeneity (IH) for five lymphocyte phenotypes
Biomarker Phenotype Analytical
goal for
precision
(%)
bias
(%)
TEa (%) RCV (%) R II IH
p < 0.05 p < 0.01 P < 0.05
CD3 (T cells) 1.8 2.8 5.8 7.0 11.1 0.89 0.34 0.06
CD4 3.1 5.4 10.5 12.6 19.2 0.90 0.33 0.11
CD8 3.4 9.0 14.6 16.8 19.8 0.96 0.20 0.11
CD19 (B 8.7 9.1 23.4 29.4 49.6 0.76 0.56 0.28
cells) CD56/16 (NK cells) 11.5 10.9 29.9 37.7 65.7 0.71 0.64 0.37
Table 3 Analytical goals for imprecision, bias, total error allowable (TEa) for p < 0.01 and p < 0.05, reference change value (RCV),
Reliability coefficient (R), indices of individuality (II), and index of heterogeneity (IH) for eighteen serum biomarkers
Biomarker Analytical
goals for
precision
(%)
bias
(%)
TEa (%) RCV(%) R II IH
p < 0.01 p < 0.05 95
Group I IL-1β 15.4 10.1 35.5 46.0 95.6 0.38 1.14 0.49
IL-6 10.6 8.5 26.2 33.6 66.6 0.55 0.85 0.35
IL-1Ra 8.5 11.6 25.6 31.4 52.7 0.84 0.42 0.28
IFN-γ 15.5 9.5 35.1 45.6 96.0 0.29 1.52 0.53
TNF-α 6.3 7.5 17.9 22.2 39.3 0.79 0.55 0.24
Group II IL-8 (CXCL8) 25.7 14.9 57.3 74.8 159.2 0.22 1.70 0.81
MIP-1β (CCL4) 10.0 15.1 31.6 38.4 61.9 0.87 0.36 0.32
RANTES (CCL5) 12.0 11.4 31.2 39.4 74.3 0.68 0.62 0.38
Group III Adiponectin 7.95 12.7 25.8 31.2 45.2 0.90 0.34 0.26
Leptin 15.5 18.7 44.3 54.8 96.0 0.79 0.47 0.50
Group IV sCD14 4.0 3.5 10.1 12.8 24.8 0.62 0.74 0.13
sCD40L 4.7 5.2 12.9 16.1 38.8 0.52 0.54 0.21
sCD163 4.5 13.6 21.1 24.1 27.9 0.97 0.24 0.21
sgp130 3.5 4.1 9.9 12.3 21.7 0.79 0.57 0.13
sIL-2Rα 7.55 11.1 23.5 28.7 46.8 0.86 0.37 0.24
sIL-6R 8.16 6.5 20.0 25.5 50.5 0.55 0.81 0.26
sTNF-RII 8.7 8.4 22.8 28.7 53.9 0.69 0.70 0.32
Group V Neopterin 17.5 12.7 41.6 53.5 108.4 0.47 0.96 0.56
Group I represents cytokines, Group II is chemokines, group III is adipocytokines, group IV represents soluble cell receptors, and group V is immune
activation markers
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cautiously interpreted if using an established reference
values. In general, comparison of a patient’s laboratory
results with previous ones will be a better choice.
Materiel and methods
Specimens
The study was approved by the institutional review
board (IRB) for human studies at UCLA and informed
consent was obtained from twelve self-reported healthy
volunteers, including six men (21, 32, 33, 40, 42, and 51
years old, with weight of 175, 190, 165, 178, 172, and
194 lbs. and body mass index (BMI) of 25.1, 26.5, 22.4,
27.1, 26.9, and 26.3, respectively) and six women (23, 24,
39, 41, 47, 47 years old, weight of 142, 123, 143, 139,
141, and 140 lbs. and BMI of 24.4, 19.9, 22.4, 23.8, 24.2,
and 24.0, respectively). The individuals all self-reported
no health problems or menstrual cycle at the time of
blood collection. Blood was collected into one 10mL
serum separator tube (SST) and one 4 mL vacutainer
tube containing EDTA (Becton Dickinson Vacutainer
System Franklin Lakes, NJ) to obtain serum and whole
blood, respectively. Blood was collected according to the
Clinical and Laboratory Standards Institute (CLSI)
standard by phlebotomist between 9:00 am and 11:00 am
(to prevent any circadian rhythm variation) once a week
from the twelve subjects for a total of six weeks (subject
#11 missed visit #4 of his blood draw). The SST blood
tube from each individual was centrifuged within one
hour after collection (500 x g for 10 min) and the serum
was separated and frozen at -70 °C until batch analysis.
EDTA whole blood was used to determine cell surface
markers on lymphocytes by flow cytometry.
Method of measurement
Serum concentrations of each biomarker were deter-
mined using commercially available enzyme- linked
immunosorbent assays (ELISA) and all serum samples of
each individual were batched and tested in duplicate in a
single assay (IL-1β, IL-8, and sIL-6R tested singleton).
The detailed instructions of each assay procedure are
available through the manufactures’ website and all the
assays were performed according to the manufacturer’s
instructions. The MDD, intra-assay data of TNF-α, IFN-
γ and IL-12p70 and neopterin are from our lab (pool of
serum) while the rest of the data is from the manufac-
turer (R&D Systems) and the method of measurement
for each biomarker is summarized in Table 6 while their
clinical and research significance along with publication
references for each biomarker is included as supplemen-
tary text in Additional file 4.
Flow cytometry
Flow cytometric analysis was performed using a FACSCa-
libur analyzer and CellQuest software (BDIS, San Jose,
CA) [28]. In summary for each sample, 50 μl of blood was
stained with BD monoclonal antibodies conjugated with
immunofluorescence such as fluorescein isothiocyanate
(FITC) or phycoerythrin (PE), or Peridinin Chlorophyll
Protein Complex (PerCP) or Allophycocyanin (APC), (BD
Biosciences, San Jose, CA) using lyse no wash sample
preparation method, with lymphocyte gating done accord-
ing to the manufacturer’s instructions. CD3-FITC, CD8-
PE, CD45-PerCP, and CD4-APC were used to label T cells
in the first sample. In the second sample, CD3-FITC,
CD56/16-PerCP, and CD19-APC monoclonal antibodies
were used for identification of natural killer (NK) cells and
B cells. The percentages of CD3+/CD4+ (helper T-cell),
CD3+/CD8+ (cytotoxic T-cell), CD3−/CD56/16+ (natural
killer cell), and CD3−/CD19+ (B-cell) cells were deter-
mined by flow cytometric analysis.
Statistical analysis
A four-parameter curve-fitting program was used for gen-
eration of calibration curves and computation of unknown
concentrations of each biomarker. The SigmaPlot software
(Jandel Scientific, San Rafael, CA, USA) package was used
for all plots. STATA, version 14.23 (StataCorp LLC, Col-
lege Station, Texas), was used for Spearman’s correlation
to assess the relationship among serum levels and cell
surface markers. SAS, version 9.3 (SAS Institute, Inc.,
Table 5 Previous studies examining/reporting the intra-individual (CVI) and inter-individual (CVG) variation of some biomarkers
Biomarker CVI (%)
Pub. Our
CVG (%)
Pub. Our
Subject/ Visit/Period
(6 m + 6f) / (6v-6w)
Reference
Adiponectin 18.8 15.9 51.2 48.1 (7 m + 15f)/(2v-15mo) Shand et al. [14]
IL-1β 30.0 30.9 36.0 27.0 (4 m + 11f)/(6v-6mo) Gonzalez et al. [15]
IL-8 24.0 54.4 31.0 30.2 (4 m + 11f)/(6v-6mo) Gonzalez et al. [15]
IL-6 48.5 21.5 39.4 26.4 (4 m + 11f)/(6v-6mo) Cava et al. [16]
TNF-α 43.0 12.7 29.0 27.2 (4 m + 11f)/(6v-6mo) Gonzalez et al. [15]
sIL-2Rα 5.8 15.1 38.8 41.7 (4 m + 11f)/(6v-6mo) Cava et al. [16]
sCD163 9.0 15.9 35.9 48.1 (0 m + 12f)/(12v-35d) Moller et al. [17]
m male, f female, v visit, w week, mo month, Pub published data, Our our data, d day
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Cary, North Carolina) was used for ANOVA to calculate
intra-individual, inter-individual, and analytical variance
(i.e. between duplicates). The data for each marker were
checked for outlier results exceeding ±3SD from the
mean. One data point of sCD40L (week 5) of a subject
was ranked as outlier due to a technical problem and
excluded from data analysis. All results of the markers fell
within the appropriate range of ±2SD from the mean.
The coefficients of variation (CV) of analytical (CVA),
intra-individual (CVI), and inter-individual (CVG) com-
ponents were calculated according to the approach by
Harris and Boyd [29].
The index of individuality (II) is the sample ratio CVI
to CVG and was calculated by the following formula:
II = √ (CVA
2 + CVI
2)/CVG) for a majority of the bio-
markers and simply by CVI/CVG for IL-1β, IL-8, sIL-6R,
and lymphocyte phenotypes [9]. Examining the hetero-
geneity of within-subject variation for a given biomarker,
the index of heterogeneity (IH) was calculated as the
observed CV of the set of individuals’ variance to the
theoretical CV using the formula of:
IH = CVT /√(2/[n-1]) where CVT = √ (CVA
2 + CVI
2)
and n is the average number of observations (samples)
per subject. Since the number of samples per subject in
our study was 6, an IH < 1.58 indicates that the CVI data is
homogeneous for a biomarker because the index is < {1 +
2[1/(2n)1/2]} [12, 26]. The critical difference or reference
change value (RCV) was calculated using the following for-
mula: RCV= 21/2*Z*(CVA
2 + CVI
2)1/2 and the Z-score for a
probability of 95% or p < 0.05 was 1.96 while the Z-score
for p < 0.01 or probability of 99% was 2.56 (bidirectional).
The reliability coefficient (R) is the ratio of between-
subject variation to total variation. It is another measure-
ment of individuality and calculated as: R = CVG
2/
CVA
2 + CVI
2 + CVG
2.
The value of R ranged between 0 and 1. When R
approaches 1, this means that there is very little intra-in-
dividual variation of results over time, while also indicat-
ing that great confidence can be placed in a single result
with no need for repeat measurement [30].
The analytical imprecision (CVA), bias (BA), and total
error allowable (TEa) for each biomarker based on
Table 6 Suppliers of biomarker assays, minimum detectable dose (MDD), Intra-assay coefficient of variation (CV %), and mean
concentration of biomarker sample #1 and 2 of the kits
Supplier of biomarkers MDD Intra-Assay Precision Assayed
A. Cytokines/Chemokines Sample #1 (CV%, mean) Sample #2 (CV%, mean)
1 Interleukin-1ß (IL-1 ß)a 0.033 pg/mL 4.4, 0.315 pg/mL (n = 20) 3.9, 1.30 pg/mL (n = 20) singleton
1 Interleukin-6 (IL-6)a 0.039 pg/mL 6.9, 0.436 pg/mL (n = 20) 7.8, 2.45 pg/mL (n = 20) duplicate
2 Interleukin-12 (IL-12p70) 2.1 pg/mL 5.0, 15.85 pg/mL (n = 8) 2.13, 45.0 pg/mL (n = 8) duplicate
1 IL-1 receptor antagonist 6.3 pg/mL 7.3, 66.9 pg/mL (n = 20) 5.0, 607 pg/mL (n = 20) duplicate
2 Interferon-γ (IFN-γ) 0.03 IU/mL 3.2, 1.26 IU/mL (n = 20) 3.8, 12.28 IU/mL (n = 20) duplicate
2 Tumor Necrosis Factor-α 3.0 pg/mL 5.2, 86.7 pg/mL (n = 20) 3.7, 591 pg/mL (n = 20) duplicate
1 Interleukin-8 (IL-8)a 0.13 pg/mL 5.5, 5.5 pg/mL (n = 20) 7.3, 37.1 pg/mL(n = 20) singleton
1 CCL3 (MIP-1 α) 10.0 pg/mL 8.9, 140 pg/mL (n = 20) 8.8, 688 pg/mL (n = 20) duplicate
1 CCL4 (MIP-1 β) 11.0 pg/mL 9.0, 51.3 pg/mL (n = 20) 3.6, 208 pg/mL (n = 20) duplicate
1 CCL5 (RANTES) 2.0 pg/mL 2.5, 91.9 pg/mL (n = 20) 1.7, 573 pg/mL (n = 20) duplicate
B. Adipocytokines
1 Adiponectin 0.25 ng/mL 2.5, 19.8 ng/mL (n = 20) 3.4, 69.9 ng/mL (n = 20) duplicate
1 Leptin 7.8 pg/mL 3.3, 64.5 pg/mL (n = 20) 3.0, 146 pg/mL (n = 20) duplicate
C. Soluble Receptors markers
1 sCD14 125 pg/mL 6.4, 1111 pg/mL (n = 20) 4.8, 2158 pg/mL (n = 20) duplicate
1 sCD25 (sIL-2Ra) 125 pg/mL 6.1, 207 pg/mL (n = 20) 6.1, 613 pg/mL (n = 20) duplicate
1 sCD40L 10 pg/mL 5.1, 430 pg/mL (n = 20)) 4.5, 1212 pg/mL (n = 20) duplicate
1 sCD120b (sTNF-RII) 4.2 pg/mL 3.2, 68.7 pg/mL (n = 20) 2.6, 179 pg/mL (n = 20) duplicate
1 sCD126 (sIL-6R) 0.6 pg/mL 8.6, 134 pg/mL (n = 20) 2.6, 644 pg/mL (n = 20) singleton
1 sCD130 (spg130) 6.5 pg/mL 4.3, 0.70 ng/mL (n = 20) 5.5, 1.82 ng/mL (n = 20) duplicate
1 sCD163 0.08 ng/mL 3.8, 20.0 ng/mL (n = 20) 3.4, 35.1 ng/mL (n = 20) duplicate
D. Immune Activation markers
3 Neopterin 2.0 nmol/L 7.4, 4.5 nmol/L (n = 10) 5.6, 18.7 nmol/L (n = 10) duplicate
aHigh sensitivity ELISA; 1: R&D Systems Inc., USA (A1, B1, C1); 2: Thermo Fisher Scientific, USA (A2); 3: B.R.A.H.M.S., Germany (D3)
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biological variation for desirable quality specifications
were calculated using the following formulas [11, 31]:
Precision: CVA<0.50 CVI
Bias: BA<0.250 x (CV1² + CVG²)
1/2
Total Error Allowable (TEa):
For p<0.05: TEa<0.250(CVI
2+CVG
2)1/2+1.65(0.50CV1)
For p<0.01: TEa<0.250(CVI
2+CVG
2)1/2+2.33(0.50CV1)
For biomarkers in which the desirable quality specifi-
cations cannot easily be met using general methodology
and technology, use of minimum quality specifications
would be appropriate, whereas when they are easily met,
optimum quality specifications should be used [9].
Additional files
Additional file 1: Table S1a + b. The mean, median, and inter quartile
range (IQR) values of eighteen serum biomarkers (IL-1β, IL-6, IL-1ra, IFN-γ,
TNF-α, IL-8, MIP-1β, RANTES, Adiponectin, Leptin, sCD14, sCD40L, sCD163,
spg130, sIL-2Rα, sIL-6R, sTNF-RII, and neopterin) and five lymphocyte
phenotypes (CD3, CD4, and CD8 T-cell, CD19 B-cell, and CD56/16 NK cell)
were calculated and presented for six males, six females, and both
genders. (DOCX 18 kb)
Additional file 2: Table S2. The Spearman’s correlation was assessed to
determine the relationship among the eighteen serum biomarkers and
five lymphocyte phenotypes of 12 subjects with six visits (total of 71
observations for each marker). There were both positive and negative
statistically significant (p < 0.05) correlation coefficients (r) ranging from
very weak to strong as well as instances of no correlation among the
biomarkers. (DOCX 18 kb)
Additional file 3: Figure S1 and Figure S2. There were strong positive
correlation coefficients (r) between serum levels of IL-1ra and TNF-α (r =
0.65, p < 0.001), and percentage CD4+ T-cell and CD3 T-cell (r = 0.49, p <
0.001), a strong negative correlation coefficient between serum levels of
sIL-6R and percentage of CD4+ T-cell (r = − 0.65, p < 0.001), and between
percentage of CD56/16 and CD4+ T-cell (r = − 0.58, p < 0.001). Moderate
correlation was seen between serum levels of MIP-1β and sCD14,
between serum levels of sIL-2Rα and sCD14, and between serum levels
of IFN-γ and IL-6, while no correlation was seen between serum levels of
sCD40 and CD4+ T-cell. (ZIP 2800 kb)
Additional file 4: Method of measurement for each serum biomarker,
suppliers of assay kits, and clinical and research significance of each
biomarker along with their publication references are presented in
Additional file 4. (DOCX 36 kb)
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